Evidence mapPaperPMID 33920733Full record

ReviewInternational journal of molecular sciences2021

Genetics of Cardiovascular Disease: How Far Are We from Personalized CVD Risk Prediction and Management?

Michal Vrablik, Dana Dlouha, Veronika Todorovova, Denes Stefler, Jaroslav A Hubacek

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05515653 (Impact of the Genetic Background as a Risk Factor for Atherosclerotic Cardiovascular Disease in the Brazilian Population), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05515653 unknown statusnot on this mapstarted 2022, after this paper: background citation

Impact of the Genetic Background as a Risk Factor for Atherosclerotic Cardiovascular Disease in the Brazilian Population

TypeobservationalSponsorHospital Alemão Oswaldo CruzRan2022 to 2024Enrolled3,974ConditionsCardiovascular Diseases, Acute MI, Stroke, Peripheral Arterial DiseaseArmsExposure to genetics (polygenic)
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Michal Vrablik3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, 11636 Prague, Czech Republic.
Dana DlouhaExperimental Medicine Centre, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic.
Veronika Todorovova3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, 11636 Prague, Czech Republic.
Denes SteflerDepartment of Epidemiology and Public Health, Institute of Epidemiology and Health Care, University College London, London WC1E 7HB, UK.ORCID 0000-0001-6537-1353
Jaroslav A Hubacek3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, 11636 Prague, Czech Republic.
Charles University · CZInstitute of Clinical and Experimental Medicine · CZUniversity College London · GB

Funding

Ministerstvo Zdravotnictví Ceské Republiky conceptual development of research organization 64165Ministerstvo Zdravotnictví Ceské Republiky IN 00023001Ministerstvo Zdravotnictví Ceské Republiky NU-20-06-00061Ministerstvo Zdravotnictví Ceské Republiky NV17-28882AMinisterstvo Zdravotnictví Ceské Republiky NV18-01-00046
6 · The paper itself

Abstract

Despite the rapid progress in diagnosis and treatment of cardiovascular disease (CVD), this disease remains a major cause of mortality and morbidity. Recent progress over the last two decades in the field of molecular genetics, especially with new tools such as genome-wide association studies, has helped to identify new genes and their variants, which can be used for calculations of risk, prediction of treatment efficacy, or detection of subjects prone to drug side effects. Although the use of genetic risk scores further improves CVD prediction, the significance is not unambiguous, and some subjects at risk remain undetected. Further research directions should focus on the "second level" of genetic information, namely, regulatory molecules (miRNAs) and epigenetic changes, predominantly DNA methylation and gene-environment interactions.

Indexed as

AnimalsCardiovascular DiseasesGenetic Predisposition to DiseaseGenetic TestingGenome-Wide Association StudyHumansNutrigenomicsPrecision Medicinecardiovascular diseaseepigeneticgenegene scoreinteractionpolymorphism

Identifiers

PMID33920733
PMCPMC8074003
OpenAlexW3154485293

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.